# Contrast Enhanced Ultrasound Evaluation of Brain Perfusion in Neonatal Post-Hemorrhagic Hydrocephalus

> **NCT03061045** · PHASE4 · WITHDRAWN · sponsor: **Johns Hopkins University**

## Conditions studied

- Neonatal Post-Hemorrhagic Hydrocephalus

## Interventions

- **DRUG:** Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]

## Key facts

- **NCT ID:** NCT03061045
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-04-01
- **Primary completion:** 2018-01-22
- **Final completion:** 2018-01-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI is leaving the institution
- **Last updated:** 2018-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061045, "Contrast Enhanced Ultrasound Evaluation of Brain Perfusion in Neonatal Post-Hemorrhagic Hydrocephalus". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03061045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*